📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
6 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
24
DYN Stock Analysis & AI Grade: HIGH
6 articles analyzed · Sentiment: NEUTRAL · AI-powered equity research
RECENT COVERAGE · 6 ARTICLES
Dyne Therapeutics GAAP EPS of -$1.08 misses by $0.33 (NASDAQ:DYN)
Dyne Therapeutics (DYN) reported Q2 GAAP EPS of -$1.08, missing consensus estimates by $0.33. This represents a significant earnings...
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics (DYN) successfully closed an upsized public offering, raising approximately $431.4 million gross proceeds through the...
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Dyne Therapeutics (DYN) announced an upsized equity offering of 18.3 million shares priced at $20.50 per share, generating approximately...
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Dyne Therapeutics (DYN) has initiated a $300 million underwritten public offering with an additional $45 million overallotment option,...
Dyne Therapeutics: A Buy, With Caveats, On DMD Progress (NASDAQ:DYN)
Dyne Therapeutics (DYN) has secured FDA Priority Review designation for z-rostudirsen, its muscular dystrophy therapeutic candidate....
Dyne Therapeutics (DYN) Inspires Confidence With Its Force Platform
Dyne Therapeutics (DYN) received analyst initiation coverage from TD Cowen with a Buy rating, driven by confidence in the company's...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice